• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    EXL Announces Appointment of Andreas Fibig to Board of Directors

    1/12/23 4:01:00 PM ET
    $EXLS
    $IFF
    $NVO
    Real Estate
    Real Estate
    Major Chemicals
    Industrials
    Get the next $EXLS alert in real time by email

    NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees.

    "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We look forward to the insights and contributions Andreas will bring to the Board and leadership team as the company executes on its growth strategy."

    EXL Vice Chairman and Chief Executive Officer Rohit Kapoor said, "We are delighted to welcome Andreas to our Board of Directors. His years of experience leading large global organizations will provide us with valuable insight and perspective as we rapidly scale EXL into the dominant global player in analytics and digital operations. Andreas also brings a unique combination of experience in international markets along with a deep understanding of U.S. business, which will benefit EXL as we continue our geographic expansion, particularly in Europe."

    "I'm truly excited to join the EXL Board at this stage in the company's journey," said Fibig. "EXL's transformation to a data-led analytics and digital operations company has resulted in remarkable growth and significant improvement in profitability. I look forward to working with the Board and management team to help the company continue its growth trajectory as well as create sustainable competitive advantage through its digital strategy. I am also honored to be part of an organization that focuses on sustainability as part of its enterprise strategy, and I'm excited to help further those efforts."

    Fibig spent 10 years with International Flavors & Fragrances (NYSE:IFF), an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as Chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S (NYSE:NVO), where he is an independent director and member of the Research and Development Committee. He also serves as a director of Indigo Agriculture and EvodiaBio, which are private companies. He previously served on the board of Bunge Limited, a leading global agribusiness and food company.

    About EXL

    EXL (NASDAQ:EXLS) is a leading data analytics and digital operations and solutions company that partners with clients to improve business outcomes and unlock growth. By bringing together deep domain expertise with robust data, powerful analytics, cloud, artificial intelligence ("AI") and machine learning ("ML"), we create agile, scalable solutions and execute complex operations for the world's leading corporations in industries including insurance, healthcare, banking and financial services, media, and retail, among others. Focused on driving faster decision-making and transforming operating models, EXL was founded on the core values of innovation, collaboration, excellence, integrity and respect. Headquartered in New York, our team is over 43,100 strong, with more than 50 offices spanning six continents. For more information, visit www.exlservice.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to successfully close and integrate strategic acquisitions, our ability to respond to and manage public health crises, including the outbreak and continued effects of COVID-19 pandemic, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

    © 2023 ExlService Holdings, Inc. All rights reserved. For more information go to www.exlservice.com/legal-disclaimer

    Contacts

    Media 

    Keith Little

    Senior Manager, Media Relations

    +1 703-598-0980 

    [email protected]

    Investor Relations

    John Kristoff

    +1 212 209 4613

    [email protected]



    Primary Logo

    Get the next $EXLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXLS
    $IFF
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    9/29/2025$47.00Equal-Weight → Underweight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    9/17/2025Hold → Buy
    Berenberg
    Novo Nordisk A/S
    $NVO
    9/16/2025Neutral → Buy
    Rothschild & Co Redburn
    Novo Nordisk A/S
    $NVO
    9/9/2025Mkt Perform → Outperform
    Bernstein
    International Flavors & Fragrances Inc.
    $IFF
    9/8/2025Underperform → Peer Perform
    Wolfe Research
    Novo Nordisk A/S
    $NVO
    8/13/2025$54.00Underperform → Neutral
    BNP Paribas Exane
    International Flavors & Fragrances Inc.
    $IFF
    8/7/2025Outperform → Perform
    Oppenheimer
    Novo Nordisk A/S
    $NVO
    8/5/2025Buy → Neutral
    UBS
    More analyst ratings

    $EXLS
    $IFF
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $1,001,183 worth of shares (15,450 units at $64.80) (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/8/25 6:49:19 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $993,714 worth of shares (15,300 units at $64.95), increasing direct ownership by 25% to 77,370 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/7/25 6:59:38 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director O'Byrne Kevin bought $342,240 worth of shares (4,500 units at $76.05), increasing direct ownership by 141% to 7,696 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    5/23/25 4:46:40 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novo Nordisk A/S downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Novo Nordisk A/S from Equal-Weight to Underweight and set a new price target of $47.00

    9/29/25 9:51:57 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Berenberg

    Berenberg upgraded Novo Nordisk A/S from Hold to Buy

    9/17/25 7:53:16 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Rothschild & Co Redburn

    Rothschild & Co Redburn upgraded Novo Nordisk A/S from Neutral to Buy

    9/16/25 8:00:10 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    9/10/25 6:05:04 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    8/19/25 8:35:12 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    8/14/25 6:00:12 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EXL Named a Leader in NelsonHall's 2025 NEAT Evaluation for Property & Casualty Operations: Analytics & AI

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, has been recognized as a Leader by NelsonHall in its 2025 NEAT Evaluation for P&C Operations: Analytics & AI. The recognition highlights EXL's commitment to innovation and its ability to embed powerful analytics and AI-driven solutions into the enterprise workflows of the world's leading property and casualty (P&C) insurers. The annual report leverages the NelsonHall Vendor Evaluation and Assessment Tool (NEAT) to evaluate companies on their ability to deliver immediate impact and future-ready solutions to P&C clients. Leaders outperform their peers by driving innovation to improve firms' underwr

    9/30/25 10:33:25 AM ET
    $EXLS
    Real Estate

    EXL Recognized as a Leader by Everest Group in its Healthcare Data, Analytics and AI Services PEAK Matrix® Assessment 2025

    NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, has been recognized by Everest Group as a Leader in its Healthcare Data, Analytics and AI Services PEAK Matrix® Assessment 2025. The Everest Group report highlights EXL's comprehensive portfolio of healthcare analytics solutions and platform solutions. The report cites EXL's focus on data, analytics as well as its deep domain expertise and robust partner ecosystem as key strengths. "In healthcare, maximizing the value of data is essential for better patient outcomes and operational efficiency. Yet, issues such as fragmentation, silos and lack of standardization hinder progress, which is driving

    9/17/25 10:01:21 AM ET
    $EXLS
    Real Estate

    EXL teams with InsureMO to help insurers modernize data architecture and speed AI integration

    SYDNEY and NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, has announced a teaming agreement with InsureMO, the world's leading insurance middleware platform. This collaboration is designed to provide insurers worldwide with a faster, more flexible path to core system modernization, AI integration and digital transformation. By combining EXL's deep insurance domain expertise and AI capabilities with InsureMO's cloud native digital infrastructure and ecosystem of pre-built products and APIs, insurers can accelerate innovation, simplify policy administration and modernize their legacy systems without disruption or downtime. A Future-Ready Platf

    9/10/25 11:16:58 AM ET
    $EXLS
    Real Estate

    $EXLS
    $IFF
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President of EXL Bhalla Vikas sold $350,080 worth of shares (8,000 units at $43.76), decreasing direct ownership by 6% to 127,046 units (SEC Form 4)

    4 - ExlService Holdings, Inc. (0001297989) (Issuer)

    9/12/25 5:02:13 PM ET
    $EXLS
    Real Estate

    SEC Form 4 filed by Director Mantas Jesus B

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    9/3/25 8:09:28 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 4 filed by Director Fribourg Paul J

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    9/3/25 8:09:26 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Financials

    Live finance-specific insights

    View All

    IFF Declares Dividend for Third Quarter 2025

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 10, 2025 to shareholders of record as of September 29, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All R

    7/30/25 4:20:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    EXL Reports 2025 Second Quarter Results

    2025 Second Quarter Revenue of $514.5 Million, up 14.7% year-over-year Q2 Diluted EPS (GAAP) of $0.40, up 43.9% from $0.28 in Q2 of 2024 Q2 Adjusted Diluted EPS (Non-GAAP) (1) of $0.49, up 20.3% from $0.40 in Q2 of 2024 NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a global data and AI company, today announced its financial results for the quarter ended June 30, 2025. Chairman and Chief Executive Officer Rohit Kapoor said, "I am pleased to report another strong quarter as we delivered revenue growth of 15% and increased our adjusted diluted EPS by 20%. Our sustained double-digit growth demonstrates the strength of our competitive position as a glo

    7/29/25 4:01:00 PM ET
    $EXLS
    Real Estate

    EXL Schedules Second Quarter 2025 Financial Results Conference Call

    NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a global data and AI company, will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, after the market closes. An earnings news release, investor fact sheet and presentation will be published on the company's investor relations website offering an overview of the financial results. The company will host a conference call at 10:00 a.m. EDT the following day, Wednesday, July 30, 2025, with Chairman and Chief Executive Officer Rohit Kapoor and Executive Vice President and Chief Financial Officer Maurizio Nicolelli, who will provide insights into the company's o

    7/15/25 8:02:00 AM ET
    $EXLS
    Real Estate

    $EXLS
    $IFF
    $NVO
    Leadership Updates

    Live Leadership Updates

    View All

    IFF Appoints Paul J. Fribourg and Jesus B. Mantas to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Paul J. Fribourg and Jesus B. Mantas to its board of directors, effective immediately. These appointments bring extensive international leadership experience, and industry and strategic insight to IFF as the company continues to advance its innovation agenda and strengthen its market position. "I am delighted that Paul and Jesus are joining the IFF board," said Kevin O'Byrne, chair of the IFF board. "They bring a strong combination of digital innovation, global market insight and operational excellence. Their experience, leadership and vision will help guide

    7/30/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF Appoints Virginia "Gina" Drosos to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

    6/9/25 5:46:00 PM ET
    $IFF
    $PG
    $SIG
    Major Chemicals
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary

    IFF Appoints Two New Fine Fragrance Perfumers

    Alexandra Carlin and Alex Lee join the Paris-based fine fragrance team, bringing fresh artistic perspectives PARIS, Nov. 4, 2024 /PRNewswire/ -- IFF (NYSE:IFF) proudly welcomes Alexandra Carlin as Senior Fine Fragrance Perfumer and Alex Lee as Fine Fragrance Perfumer to its Paris-based team. These strategic additions aim to enhance the Company's creative prowess in the world of perfumery. "We're excited for the talent and creative energy that Alexandra and Alex will bring to IFF Scent," said Sabrya Meflah, president, Fine Fragrance, IFF. "Alexandra's ability to translate deep

    11/4/24 4:00:00 AM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ExlService Holdings Inc.

    SC 13G/A - ExlService Holdings, Inc. (0001297989) (Subject)

    11/12/24 9:55:17 AM ET
    $EXLS
    Real Estate

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    3/8/24 4:44:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    2/13/24 5:07:58 PM ET
    $IFF
    Major Chemicals
    Industrials